---
title: "Johnson & Johnson Posts 74% One-Year Disease-Free Survival Rate in INLEXZO Trial"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/268805046.md"
description: "Johnson & Johnson Posts 74% One-Year Disease-Free Survival Rate in INLEXZO Trial"
datetime: "2025-12-05T22:00:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/268805046.md)
  - [en](https://longbridge.com/en/news/268805046.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/268805046.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/268805046.md) | [English](https://longbridge.com/en/news/268805046.md)


# Johnson & Johnson Posts 74% One-Year Disease-Free Survival Rate in INLEXZO Trial



### 相關股票

- [Johnson & Johnson (JNJ.US)](https://longbridge.com/zh-HK/quote/JNJ.US.md)

## 相關資訊與研究

- [Johnson & Johnson Submits OTTAVA Robotic Surgical System for FDA De Novo Review](https://longbridge.com/zh-HK/news/271792254.md)
- [Johnson & Johnson Submits EMA Application for Teclistamab and Daratumumab Combo in Relapsed Multiple Myeloma](https://longbridge.com/zh-HK/news/271654864.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/zh-HK/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/zh-HK/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/zh-HK/news/281406751.md)